Cellectis (CLLS) Non Operating Interest Expenses (2021 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.58 Bn | 130.73 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.33 Bn | 77.33 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.43 Bn | 58.24 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.84 Bn | 52.70 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.93 Bn | 34.83 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.47 Bn | 32.16 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.39 Bn | 27.56 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Cellectis | 325.91 Mn | 159.06 Mn | - | -3.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.01 Mn |
| Mar 31, 2026 | -4.44 Mn |
| Dec 31, 2025 | -11.41 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Jun 30, 2024 | 16.65 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Dec 31, 2023 | -17.56 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 16.28 Mn |
| Mar 31, 2023 | -5.18 Mn |
| Dec 31, 2022 | -13.68 Mn |
| Sep 30, 2022 | -1.09 Mn |
| Jun 30, 2022 | 1.69 Mn |
| Mar 31, 2022 | -1.36 Mn |
| Mar 31, 2021 | -1,000.00 |